We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
Future Cardiology 2018 May
AIM: To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital.
METHODS: Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital.
RESULTS: 189 patients (age 76.0 ± 9.4 years; CHA2 DS2 -VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74.1% of patients. Among patients treated with rivaroxaban 20 and 15 mg, only 3.6 and 22.5%, respectively, received an inadequate dose. After 26.6 ± 11.6 months of treatment, annual discontinuation rate was 1%. Rates of stroke, major bleeding and intracranial hemorrhage were 0.45, 0.22 and 0.22 events/100 patient years, respectively.
CONCLUSION: In our practice of regional hospital, rates of discontinuation, thromboembolic and bleeding outcomes are low.
METHODS: Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital.
RESULTS: 189 patients (age 76.0 ± 9.4 years; CHA2 DS2 -VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74.1% of patients. Among patients treated with rivaroxaban 20 and 15 mg, only 3.6 and 22.5%, respectively, received an inadequate dose. After 26.6 ± 11.6 months of treatment, annual discontinuation rate was 1%. Rates of stroke, major bleeding and intracranial hemorrhage were 0.45, 0.22 and 0.22 events/100 patient years, respectively.
CONCLUSION: In our practice of regional hospital, rates of discontinuation, thromboembolic and bleeding outcomes are low.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app